1
PBMC from the Dutch patients (Patients 1-3) were stimulated in 96-well round bottom 2 plates (Corning). Cells kept in culture for more than 48hrs were supplemented with 10% pooled 3 human serum. Ruxolitinib (Invivogen) was used at concentrations ranging from 1-1000nM 4 dissolved in DMSO. All controls were adjusted for the amount of DMSO present in the sample 5 for which the control was designed.
6
PBMC isolated from US patients with STAT1 GOF (Patients 4-6) were stimulated either 7 in 96-well flat bottom plates (Corning) 10 6 /ml in 200 mcl, or in polystyrene round-bottom tubes 8 (Becton Dickinson Falcon), at 10 7 /ml in 100 mcl. Whole blood stimulation was performed in 9 polystyrene round-bottom tubes in100 mcl. Stimulation was performed with IFNγ 1b
10
(ACTIMMUNE) 400U/ml or anti-human CD3 and anti-human CD28 antibodies (E-bioscience) 1 11 mcg/ml. Liquid nitrogen-stored PBMCs from healthy donors and patients (4 and 6) were thawed 13 and cultured in RPMI 1640 with 10% FBS, 2mM L-glutamine, 100 U/mL of penicillin, and 100 14 μg/mL of streptomycin (Life Technologies) at 37°C in a humidified 5% CO2 incubator. Figure S1 
